Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Gritstone Oncology, Inc is a biotechnology business based in the US. Gritstone Oncology shares (GRTS) are listed on the NASDAQ and all prices are listed in US Dollars. Gritstone Oncology employs 176 staff and has a trailing 12-month revenue of around USD$3.6 million.
|Latest market close||USD$2.87|
|52-week range||USD$2.6 - USD$12.2|
|50-day moving average||USD$2.9815|
|200-day moving average||USD$5.0128|
|Wall St. target price||USD$11.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.208|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-15.34%|
|1 month (2020-11-06)||11.67%|
|3 months (2020-09-04)||2.87|
|6 months (2020-06-05)||-57.36%|
|1 year (2019-12-05)||-65.91%|
|2 years (2018-12-04)||-90.51%|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
Valuing Gritstone Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gritstone Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gritstone Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Gritstone Oncology shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$3.6 million|
|Gross profit TTM||USD$-78,531,000|
|Return on assets TTM||-36.62%|
|Return on equity TTM||-77.05%|
|Market capitalisation||USD$112.5 million|
TTM: trailing 12 months
There are currently 2.3 million Gritstone Oncology shares held short by investors – that's known as Gritstone Oncology's "short interest". This figure is 2.4% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting Gritstone Oncology shares can be evaluated.
Gritstone Oncology's "short interest ratio" (SIR) is the quantity of Gritstone Oncology shares currently shorted divided by the average quantity of Gritstone Oncology shares traded daily (recently around 401187.135506). Gritstone Oncology's SIR currently stands at 5.83. In other words for every 100,000 Gritstone Oncology shares traded daily on the market, roughly 5830 shares are currently held short.
However Gritstone Oncology's short interest can also be evaluated against the total number of Gritstone Oncology shares, or, against the total number of tradable Gritstone Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gritstone Oncology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Gritstone Oncology shares in existence, roughly 60 shares are currently held short) or 0.0949% of the tradable shares (for every 100,000 tradable Gritstone Oncology shares, roughly 95 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Gritstone Oncology.
Find out more about how you can short Gritstone Oncology stock.
We're not expecting Gritstone Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Gritstone Oncology's shares have ranged in value from as little as $2.6 up to $12.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gritstone Oncology's is 1.1151. This would suggest that Gritstone Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.